PCA Dealing
Summary by AI BETAClose X
14 November 2025
Futura Medical plc
("Futura", "the Group" or the "Company")
PCA Dealing
Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that Lombard Odier Asset Management (Europe) Limited, a fund closely associated with Harmesh Suniara, Non-Executive Director, has sold 4,441,678 ordinary shares of 0.2 pence each ('Ordinary Shares') in the Company on 13 November 2025 at a price of 1.5 pence per share. Following the sale, Lombard Odier Asset Management (Europe) Limited hold 82,339,520 ordinary shares representing 26.90% of the company's issued share capital.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Lombard Odier Asset Management (Europe) Limited |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Fund closely associated with Harmesh Suniara, Non-Executive Director |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Futura Medical plc |
|
b) |
LEI |
21380053QLT46UNV2303 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.2 pence each |
|
b) |
Identification Code |
GB0033278473 |
|
c) |
Nature of the transaction |
Sale of Ordinary Shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
1.5 pence and 4,441,678 |
|
e) |
Aggregated information - Aggregated volume - Price |
N/A |
|
f) |
Date of the transaction (s) |
13 November 2025 |
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
Contacts:
|
Futura Medical plc
|
Alex Duggan Interim Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Broker
|
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0)20 3100 2000
|
|
Turner Pope Investments (TPI) Ltd - Broker |
James Pope, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett Sam Modlin Emma Thompson |
+44 (0)20 3405 0205 futura@almastrategic.com |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.
WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund